Delisting risk
ALZN · NASDAQ · Biotechnology

Alzamend Neuro

Develops AL001 and ALZN002 candidates for Alzheimer’s disease and psychiatric disorders.

$1.66
After-hours close−0.04 (−2.35%)
At close$1.70(+2.10%)
DateEstimateReportedSurprise
Sep 2026−$0.56
Jul 2026−$0.67−$0.74−10.4%
Mar 2026−$0.53−$0.58−9.4%
Dec 2025−$0.83−$0.30+63.9%
Sep 2025−$3.69−$1.28+65.3%

The latest year is open to everyone — the 36 quarters behind it read with an account.

Sign in
Jul 2025
Mar 2025
Dec 2024
Sep 2024
Jul 2024
Mar 2024
Dec 2023
Sep 2023
Jul 2023
Mar 2023
Dec 2022
Sep 2022
Jul 2022
Mar 2022
Dec 2021
Sep 2021
Jul 2021
Jan 2021
Oct 2020
Jul 2020
Apr 2020
Jan 2020
Oct 2019
Jul 2019
Apr 2019
Jan 2019
Oct 2018
Jul 2018
Apr 2018
Jan 2018
Oct 2017
Jul 2017
Apr 2017
Jan 2017
Oct 2016
Jul 2016
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Sep 9, 2026−$0.56
Jul 22, 2026−$0.67−$0.74−10.4%
Mar 11, 2026−$0.53−$0.58−9.4%
Dec 9, 2025−$0.83−$0.30+63.9%
Sep 10, 2025−$3.69−$1.28+65.3%

The latest year is open to everyone — the 36 quarters behind it read with an account.

Sign in
Jul 29, 2025
Mar 10, 2025
Dec 11, 2024
Sep 11, 2024
Jul 30, 2024
Mar 25, 2024
Dec 15, 2023
Sep 13, 2023
Jul 27, 2023
Mar 15, 2023
Dec 12, 2022
Sep 13, 2022
Jul 19, 2022
Mar 15, 2022
Dec 13, 2021
Sep 13, 2021
Jul 29, 2021
Jan 31, 2021
Oct 31, 2020
Jul 31, 2020
Apr 30, 2020
Jan 31, 2020
Oct 31, 2019
Jul 31, 2019
Apr 30, 2019
Jan 31, 2019
Oct 31, 2018
Jul 31, 2018
Apr 30, 2018
Jan 31, 2018
Oct 31, 2017
Jul 31, 2017
Apr 30, 2017
Jan 31, 2017
Oct 31, 2016
Jul 31, 2016